Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Jiangsu Nata Opto-Electronic Material Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are located in 1 distinct art unit, which suggests a concentrated technical focus for the company's current patent filings. The prosecution involves 2 distinct examiners, each reviewing a pending matter. This arrangement requires the applicant to address the specific technical perspectives of different reviewers within the same administrative group.
BAHTA, MEDHANIT W is the busiest examiner for the portfolio, overseeing 1 pending office action. While there are 2 distinct examiners, the fact that they both operate within 1 distinct art unit may lead to more consistent procedural requirements. Practitioners should monitor the 2 pending office actions for any shared feedback patterns within this specific art unit. Ensuring that arguments remain consistent across the various reviewers is vital for a cohesive intellectual property strategy in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAHTA, MEDHANIT W | 1 | 80.6% | +28.2% |
| BAKSHI, PANCHAM | 1 | 76.8% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693046 | Use of Chlorine-Free Catalyst in the Preparation of Diisopropylaminosilane | BAHTA, MEDHANIT W | — |
| 18546323 | PREPARATION METHOD FOR TRIMETHYLALUMINUM | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18693046 | Use of Chlorine-Free Catalyst in the Preparation of Diisopropylaminosilane | BAHTA, MEDHANIT W | — |
| 18546323 | PREPARATION METHOD FOR TRIMETHYLALUMINUM | BAKSHI, PANCHAM | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693046 | Use of Chlorine-Free Catalyst in the Preparation of Diisopropylaminosilane | BAHTA, MEDHANIT W | — | §101 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18546323 | PREPARATION METHOD FOR TRIMETHYLALUMINUM | BAKSHI, PANCHAM | 1623 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial